Present advances and future perspectives of molecular targeted therapy for osteosarcoma

Atik Badshah Shaikh, Fangfei Li, Min Li, Bing He, Xiaojuan He, Guofen Chen, Baosheng Guo, Defang Li, Feng Jiang, Lei Dang, Shaowei Zheng, Chao Liang, Jin Liu, Cheng Lu, Biao Liu, Jun Lu, Luyao Wang, Aiping Lyu*, Ge Zhang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

101 Citations (Scopus)
24 Downloads (Pure)


Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, novel precise OS-targeting therapies are being developed with the hope of addressing this issue. This review summarizes the current development of molecular mechanisms and targets for osteosarcoma. Therapies that target these mechanisms with updated information on clinical trials are also reviewed. Meanwhile, we further discuss novel therapeutic targets and OS-targeting drug delivery systems. In conclusion, a full insight in OS pathogenesis and OS-targeting strategies would help us explore novel targeted therapies for metastatic osteosarcoma.

Original languageEnglish
Article number506
Number of pages21
JournalInternational Journal of Molecular Sciences
Issue number4
Publication statusPublished - 6 Apr 2016

Scopus Subject Areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

User-Defined Keywords

  • Molecular mechanism
  • Molecular targets
  • Osteosarcoma
  • Targeted therapy


Dive into the research topics of 'Present advances and future perspectives of molecular targeted therapy for osteosarcoma'. Together they form a unique fingerprint.

Cite this